Highlights the exponential growth of TAVR and questions the continued reliance on surgical risk scores like STS and EuroSCORE II for predicting TAVR mortality.
Transcatheter aortic valve replacement (TAVR) has proven to be an effective treatment option for patients with severe symptomatic aortic stenosis across all surgical risk levels. Surgical risk is assessed by the Society of Thoracic Surgeons Predicted Risk of Mortality (STS) score or EuroSCORE II, which are estimates of the operative mortality after surgical aortic valve replacement. TAVR has grown exponentially over the past decade to a point where the number of TAVR procedures in the United States now exceeds the total number of surgical aortic valve replacements.
No takes yet. Share an insight, caveat, or question.
Goel et al. (2023) conducted an editorial in Severe symptomatic aortic stenosis. Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: